<DOC>
	<DOC>NCT01516814</DOC>
	<brief_summary>The objective of this study is to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of rivaroxaban in the treatment of pulmonary embolism (PE) and the prevention of the occurrence and the recurrence of deep vein thrombosis (DVT) or PE in Japanese patients with acute symptomatic PE with or without symptomatic DVT.</brief_summary>
	<brief_title>Venous Thromboembolism (VTE) Treatment Study in Japanese Pulmonary Embolism (PE) Patients</brief_title>
	<detailed_description />
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Men and women &gt;/= 20 years of age in patients with confirmed acute symptomatic pulmonary embolism (PE) with or without symptomatic deep vein thrombosis (DVT) Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current episode of PE More than 48 hours prerandomization treatment with therapeutic dosages of anticoagulant treatment or more than a single dose of warfarin from the onset of the current episode of PE to randomization Calculated creatinine clearance (CLCR) &lt; 30 mL/min Subjects with hepatic disease which is associated with coagulopathy leading to a clinically relevant bleeding risk Active bleeding or high risk for bleeding contraindicating treatment with unfractioned Heparin (UFH) or warfarin Systolic blood pressure &gt; 180 mmHg or diastolic blood pressure &gt; 110 mmHg</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>acute symptomatic pulmonary embolism</keyword>
</DOC>